EP3463319A4 - Methods and compositions for eradicating leukemic cells - Google Patents

Methods and compositions for eradicating leukemic cells Download PDF

Info

Publication number
EP3463319A4
EP3463319A4 EP17807621.2A EP17807621A EP3463319A4 EP 3463319 A4 EP3463319 A4 EP 3463319A4 EP 17807621 A EP17807621 A EP 17807621A EP 3463319 A4 EP3463319 A4 EP 3463319A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
leukemic cells
eradicating leukemic
eradicating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17807621.2A
Other languages
German (de)
French (fr)
Other versions
EP3463319A1 (en
Inventor
Amir SCHAJNOVITZ
David T. Scadden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
General Hospital Corp
Original Assignee
Harvard College
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, General Hospital Corp filed Critical Harvard College
Publication of EP3463319A1 publication Critical patent/EP3463319A1/en
Publication of EP3463319A4 publication Critical patent/EP3463319A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
EP17807621.2A 2016-06-02 2017-06-02 Methods and compositions for eradicating leukemic cells Withdrawn EP3463319A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344959P 2016-06-02 2016-06-02
US201662425045P 2016-11-21 2016-11-21
PCT/US2017/035818 WO2017210636A1 (en) 2016-06-02 2017-06-02 Methods and compositions for eradicating leukemic cells

Publications (2)

Publication Number Publication Date
EP3463319A1 EP3463319A1 (en) 2019-04-10
EP3463319A4 true EP3463319A4 (en) 2020-02-19

Family

ID=60479156

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17807621.2A Withdrawn EP3463319A4 (en) 2016-06-02 2017-06-02 Methods and compositions for eradicating leukemic cells

Country Status (3)

Country Link
EP (1) EP3463319A4 (en)
CN (1) CN109715146A (en)
WO (1) WO2017210636A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115120595B (en) * 2022-08-02 2023-06-30 广西医科大学第一附属医院 Application of Liproxstatin-1 in preparation of medicines for preventing and treating leukemia and medicine composition thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1712014A (en) * 2004-06-14 2005-12-28 马文·F·刘 Use of liquiritigenin
CN101036638A (en) * 2006-03-16 2007-09-19 南京医科大学 Application of glycyrrhizin in the preparation of medicine for preventing and curing tumour
CN109223762A (en) * 2018-09-26 2019-01-18 兰州大学第医院 Glabrene is preparing the application in anticancer drug

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2285522C2 (en) * 2004-02-25 2006-10-20 Эдуард Арутюнович Петросян Method for treatment of biliary peritonitis
AU2009209031A1 (en) * 2008-01-30 2009-08-06 Oregon Health & Science University DNA repair polypeptides and methods of delivery and use
WO2012135550A1 (en) * 2011-03-30 2012-10-04 Luna Innovations Incorporated Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque
US9801922B2 (en) * 2011-08-03 2017-10-31 University Of Iowa Research Foundation Compositions and methods of treating cancer
US10683316B2 (en) * 2011-11-10 2020-06-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic catalase/superoxide dismutase mimetics and methods for treating viral infections
WO2015057862A1 (en) * 2013-10-15 2015-04-23 President And Fellows Of Harvard College Methods and compositions for eradicating leukemic cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1712014A (en) * 2004-06-14 2005-12-28 马文·F·刘 Use of liquiritigenin
CN101036638A (en) * 2006-03-16 2007-09-19 南京医科大学 Application of glycyrrhizin in the preparation of medicine for preventing and curing tumour
CN109223762A (en) * 2018-09-26 2019-01-18 兰州大学第医院 Glabrene is preparing the application in anticancer drug

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAROOQUI ARSHI ET AL: "Glycyrrhizin induces reactive oxygen species-dependent apoptosis and cell cycle arrest at G0/G1in HPV18+human cervical cancer HeLa cell line", BIOMEDICINE AND PHARMACOTHERAPY, ELSEVIER, FR, vol. 97, 6 November 2017 (2017-11-06), pages 752 - 764, XP085323772, ISSN: 0753-3322, DOI: 10.1016/J.BIOPHA.2017.10.147 *
See also references of WO2017210636A1 *

Also Published As

Publication number Publication date
CN109715146A (en) 2019-05-03
WO2017210636A1 (en) 2017-12-07
EP3463319A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
EP3534705A4 (en) Compositions and methods for cell cryopreservation
EP3534968A4 (en) Anti-bcma car t cell compositions
EP3472178A4 (en) Compositions and methods for the depletion of cd117+cells
EP3532613A4 (en) Methods and compositions for rna mapping
EP3471772A4 (en) Compositions and methods for the depletion of cells
EP3230460A4 (en) Methods and compositions for selectively eliminating cells of interest
EP3479431A4 (en) Solid electrolyte compositions
EP3212225A4 (en) Methods and compositions for modified t cells
EP3151672A4 (en) Improved t cell compositions
EP3439675A4 (en) Methods and compositions for car t cell therapy
EP3177144A4 (en) Compositions and methods for selectively depleting senescent cells
EP3713559A4 (en) Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
EP3442543A4 (en) Compositions and methods for neuralgenesis
EP3384038A4 (en) Methods and compositions for reprogramming cells
EP3340809A4 (en) Sweetening compositions
EP3096757A4 (en) Apilimod compositions and methods for using same
EP3142497A4 (en) Hydrogen-containing composition
EP3431082A4 (en) Anti-aging composition
EP3436035A4 (en) Compositions and methods for using small mobile stem cells
EP3185858A4 (en) Compositions for modulating cancer stem cells and uses therefor
EP3253389A4 (en) Apilimod compositions and methods for using same
EP3213752A4 (en) Composition for treating cancer stem cells
EP3091999A4 (en) Improved cell compositions and methods for cancer therapy
EP3455895A4 (en) Compositions and methods for electrode fabrication
EP3221345A4 (en) Metalloprotein compositions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200120

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/015 20060101AFI20200114BHEP

Ipc: C07J 63/00 20060101ALI20200114BHEP

Ipc: A61K 31/19 20060101ALI20200114BHEP

Ipc: A61P 35/02 20060101ALI20200114BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200818